Natixis’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Natixis's VRTX Position: Q2 2026 in Review
Natixis increased its Vertex Pharmaceuticals (VRTX) stake by 23% in Q2 2026, buying an estimated $4.83M and bringing the position to 59,095 shares worth $29.4M. The position accounts for 0.12% of the portfolio, ranked #120.
Natixis first reported a position in VRTX in Q2 2013 and has held it in 43 quarters since. The position peaked at $73.1M in Q4 2017. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Natixis held 59,095 shares of Vertex Pharmaceuticals worth $29.4M as of Q2 2026.
- Natixis bought 10,903 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.83M.
- Vertex Pharmaceuticals made up 0.12% of Natixis's portfolio in Q2 2026, its #120 holding.
- Natixis first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Natixis's Vertex Pharmaceuticals position peaked at $73.1M in Q4 2017.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.